{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:21:36Z","timestamp":1698225696087},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":5723,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1990,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Soluble inhibitors of lymphokine\u2010activated killer (LAK) cell induction were characterized and purified from serous fluids from healthy donors or from patients with advanced cancer. Inhibitory activity in sera from cancer patients was partially absorbed with protein A agarose or anti\u2010human IgG agarose. Following absorption, residual inhibition varied with individ ual sera, suggesting the presence of IgG\u2010related and non\u2010IgG inhibitory factors, and the proportions varied in the patient population. IgG, purified by affinity chromatography from ascitic fluids, from plasma of cancer patients, and from plasma of healthy donors, significantly inhibited IL\u20102 induction of LAK cells in a dose\u2010dependent manner. Irrespective of the sources, inhibitory activity resided in the high\u2010molecular\u2010weight IgG fraction composed of IgG aggregates and immune complexes, but not monomeric IgG Commercially prepared human IgG in aggregated form, but not in monomeric form, inhibited LAK cell induction in a dose\u2010dependent manner. In contrast, neither bovine IgG nor human albumin affected LAK cell induction, even at higher concentrations. Aggregated human IgG inhibited LAK cell induction in unfractionated peripheral blood mononuclear cells (PBMC) but not in monocytedepleted peripheral blood lymphocytes (PBL). Despite exten sive (&gt;99%) depletion of IgG by protein\u2010G affinity chromatography, the serous fluid from cancer patients displayed significant inhibitory activity. Fractionation of the IgG\u2010depleted inhibitory materials by Sephacryl S\u2010300, high\u2010pressure ionexchange column (HPIEC) or gel\u2010permeation chromatography (HPGPC) demonstrated a 65\u2010kDa inhibitor, distinct from IgG. Affigel\u2010blue affinity chromatography of the 65\u2010kDa fraction depleted albumin but did not remove the inhibitory activity, suggesting that the 65\u2010kDa inhibitor is not serum albu min nor an albumin\u2010bound component. These results suggest that serous fluids from patients with advanced\u2010stage cancer contain 2 distinct regulators for LAK cell induction: (I) aggregated IgG and (2) a 65\u2010kDa inhibitor, distinct from albumin.<\/jats:p>","DOI":"10.1002\/ijc.2910460506","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T22:10:08Z","timestamp":1171923008000},"page":"785-791","source":"Crossref","is-referenced-by-count":2,"title":["Humoral modulation of lymphokine\u2010activated killer (LAK)\u2010cell induction in humans: IgG\u2010related and non\u2010IgG inhibitors in sera from cancer patients"],"prefix":"10.1002","volume":"46","author":[{"given":"Lee B.","family":"Riley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal R.","family":"Pellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stimson P.","family":"Schantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Balch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyogo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"151","article-title":"Cellular immune defects in patients with melanoma involving interleukin\u20102\u2010activated lymphocyte cy totoxicity and a serum suppressor factor","volume":"98","author":"Balch C. M.","year":"1985","journal-title":"Surgery"},{"key":"e_1_2_1_3_1","first-page":"317","article-title":"Sequential determination of circulating immune complexes in ovarian tumors","volume":"136","author":"Beaufort F.","year":"1986","journal-title":"Wien. med. Wschr."},{"key":"e_1_2_1_4_1","first-page":"4409","article-title":"Laboratory correlates of adoptive immunotherapy with recombinant interleukin\u20102 and lymphocyte activated killer cells in humans","volume":"48","author":"Boldt D. H.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830160106"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.125.2.711"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1985.00800110073005"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2030637"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205758"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205800"},{"key":"e_1_2_1_12_1","first-page":"227","article-title":"Recombinant interleukin 4 (rIL4) inhibits interleukin 2 induced activation of peripheral blood lymphocytes","volume":"7","author":"Han X.","year":"1988","journal-title":"Lymphokine Res."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199917"},{"key":"e_1_2_1_14_1","first-page":"3173","article-title":"The role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells","volume":"45","author":"Itoh K.","year":"1985","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.4049\/jimmunol.136.10.3910","article-title":"Lysis of human solid tumor cells by lymphokine\u2010activated natural killer cells","volume":"136","author":"Itoh K.","year":"1986","journal-title":"J. Immunol."},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4049\/jimmunol.134.2.802","article-title":"Leu\u201011+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL\u20102)\u2010induced activated killer (AK) cells","volume":"134","author":"Itoh K.","year":"1985","journal-title":"J. Immunol."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00915159"},{"key":"e_1_2_1_18_1","first-page":"4083","article-title":"Differential responsiveness of human breast cancer cell lines MCF\u20107 and T47D to growth factors and 17\u2010beta estradiol","volume":"48","author":"Karey K. P.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.4049\/jimmunol.142.10.3452","article-title":"IL\u20104 regulates IL\u20102 production of lymphokine\u2010activated killer activity from human lymphocytes","volume":"142","author":"Kawakami Y.","year":"1989","journal-title":"J. Immunol."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(73)90198-8"},{"key":"e_1_2_1_21_1","first-page":"373","article-title":"A comparison of the capacity of serum\u2010free media (SFM) to support human lymphocyte proliferation and generation of lymphokine\u2010activated killer (LAK) activity. (Abstract)","volume":"30","author":"McVicar D.","year":"1989","journal-title":"Proc. Amer. Ass. Cancer Res."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-341360-4.50099-8"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830110703"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(88)91261-3"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.04.040186.003341"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1979.tb00268.x"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-9558-4_4"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.6.425"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-341360-4.50098-6"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(73)90341-0"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113515"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.5.1447"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00200019"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910460506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910460506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T14:09:40Z","timestamp":1697983780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910460506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,11,15]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1990,11,15]]}},"alternative-id":["10.1002\/ijc.2910460506"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910460506","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,11,15]]}}}